Keyword: Ablynx

The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.

The setback tarnishes one of the drugs Sanofi is set to acquire through its €3.9 billion takeover of Ablynx.

Sanofi’s €45-a-share cash bid enabled it to leapfrog Novo Nordisk in the race to buy Ablynx and land its second big-ticket takeover of the month. 

NICE leader joined ABPI; Heptares co-founder will lead Merck’s new London center; Sanofi named a business transformation head.

Van Herk Investments thinks Novo’s recent offer was too low, but it will encourage Ablynx to enter talks if a sufficiently sweetened bid is received.

Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.

Novo Nordisk had takeover offers rejected by Ablynx last month, prompting it to go public with its intentions to dial up the pressure on its target.

Ablynx is gearing up to commercialize the anti-von Willebrand factor single-domain antibody in the U.S. and Europe.

The trial linked the single-domain antibody to a significant drop in time to platelet count response, bolstering Ablynx’s pitch for approval.